Table 1.
Baseline comparison of 201 KTRs prescribed de novo extended-release (N = 106) or standard-release (N = 95) tacrolimus
| Parameter | Extended-release tacrolimus (N = 106) | Standard-release tacrolimus (N = 95) | P value |
|---|---|---|---|
| Recipient age (years) | 53.4 ± 14 (22–76) | 52.6 ± 13.2 (21–77) | 0.660 |
| Donor age (years) | 45 ± 15.1 (4–81) | 44.9 ± 15.4 (8–75) | 0.940 |
| Gender M/F N (%) | 64(60)/42(40) | 52 (55)/43(45) | 0.419 |
| Dialysis duration (Years) | 4.3 ± 2.8 (0–11.0) | 5.3 ± 6.1 (0–15.0) | 0.139 |
| No. of transplants N (%) | |||
| 1 | 98(92) | 88(93) | 0.938 |
| 2 | 6(6) | 7(7) | 0.938 |
| >2 | 2(2) | 0(0) | 0.938 |
| Donor source | |||
| Live | 35(33) | 35(37) | 0.570 |
| Deceased | 71(67) | 60(63) | 0.570 |
| Body mass index (kg/m2) | 26.2 ± 5.2 (15.9–41.9) | 25.2 ± 4.6 (16–36.6) | 0.175 |
| Smoking N (%) | |||
| Previous | 31(29) | 32(34) | 0.498 |
| Current | 5(5) | 8(8) | 0.268 |
| Ethnicity N(%) | |||
| Caucasian | 59(55) | 51(54) | 0.778 |
| Black | 12(11) | 5(5) | 0.123 |
| East Asian | 16(15) | 20(21) | 0.271 |
| South Asian | 14(13) | 14(15) | 0.754 |
| Hispanic | 2(2) | 1(1) | 0.541 |
| Other | 3(3) | 4(4) | 0.439 |
| Cause of end-stage renal disease N (%) | |||
| Diabetes | 17(16) | 11(12) | 0.362 |
| Hypertension | 13(12) | 12(13) | 0.937 |
| Glomerulonephritis | 37(35) | 45(47) | 0.727 |
| Polycystic kidney disease | 12(11) | 9(9) | 0.669 |
| Interstitial nephritis | 6(5) | 2(2) | 0.178 |
| Obstructive uropathy | 5(5) | 6(6) | 0.618 |
| Unknown | 16(15) | 10(10) | 0.335 |
| Peak panel reactive antibody (%) | 21.7 ± 32.2 (0–100) | 27.9 ± 35.1 (0–100) | 0.189 |
| Cold ischemia time (h) | 10.8 ± 5.5 (2.8–30.1) | 10.4 ± 3.5 (1.5–14.7) | 0.771 |